NP / PA
Graves Gilbert Clinic PLLC
Graves Gilbert Clinic PLLC was paid $78.28M by Medicaid between Jan 2018 and Dec 2024, across 421 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 31% of everything it billed.
33Billing provider infoGRAVES GILBERT CLINIC PLLC
BOWLING GREEN, KY 42101
BOWLING GREEN, KY 42101
33aNPI1114948288assigned 07/22/2006
33bProvider typePhysician Assistant
28Total paid$78.28M
24GClaims2,734,378
24DCodes billed421
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Physician Assistant providers in Kentucky
Rank by total paid#1 of 214
Median peer was paid$134K
This provider vs. median582×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 309,494 | $9.36M | |
| 2019 | 340,923 | $10.23M | |
| 2020 | 306,317 | $9.46M | |
| 2021 | 423,191 | $12.36M | |
| 2022 | 476,260 | $12.81M | |
| 2023 | 482,898 | $13.33M | |
| 2024incomplete | 395,295 | $10.73M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 31% | 486,600 | 439,205 | $24.30M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 13% | 278,390 | 249,064 | $9.85M |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 3.8% | 195,587 | 92,984 | $3.01M |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 3.5% | 101,224 | 94,528 | $2.77M |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 3.1% | 155,625 | 146,836 | $2.39M |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 2.1% | 21,266 | 20,749 | $1.63M |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 1.9% | 22,910 | 21,324 | $1.53M |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 1.7% | 19,505 | 18,568 | $1.33M |
| 99050 | 1.7% | 22,687 | 21,672 | $1.31M | |
| 99244 | Office or other outpatient consultation, moderate to high complexity | 1.6% | 9,878 | 9,536 | $1.25M |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 1.5% | 12,947 | 12,290 | $1.21M |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | 1.4% | 1,934 | 1,758 | $1.11M |
409 more codes
| 99232 | Hospital visit by a doctor, follow-up day | 1.3% | 45,338 | $1.01M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.1% | 39,633 | $884K |
| 80050 | General health panel | 1.1% | 19,929 | $874K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.0% | 8,168 | $817K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 1.0% | 29,907 | $807K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 42,194 | $757K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 8,199 | $733K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 49,831 | $669K |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 31,393 | $663K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 20,122 | $653K |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 16,914 | $541K |
| 80053 | Comprehensive metabolic panel | <1% | 69,213 | $536K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 85,854 | $529K |
| 80061 | Lipid panel | <1% | 52,586 | $521K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 6,680 | $509K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 20,726 | $477K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 1,512 | $466K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 4,351 | $409K |
| 86235 | <1% | 5,774 | $398K | |
| 95004 | Percutaneous tests with allergenic extracts, immediate type reaction | <1% | 4,118 | $387K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 25,343 | $375K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 16,954 | $373K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 4,357 | $369K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 16,257 | $343K |
| 95806 | <1% | 2,151 | $328K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 22,913 | $324K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 23,935 | $307K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 14,656 | $301K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 2,089 | $295K |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 7,033 | $291K |
| 99173 | <1% | 5,043 | $286K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 4,880 | $281K |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 3,819 | $271K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 8,370 | $268K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 8,355 | $265K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 34,971 | $246K |
| 95886 | <1% | 2,351 | $241K | |
| 11102 | <1% | 4,698 | $222K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 2,977 | $219K |
| 76830 | Ultrasound, transvaginal | <1% | 3,147 | $214K |
| 99309 | Subsequent nursing facility care, per day, low to moderate complexity | <1% | 18,977 | $208K |
| 99233 | Hospital visit by a doctor, follow-up day (complex) | <1% | 7,095 | $203K |
| 0225U | <1% | 597 | $191K | |
| 99490 | Ccm add 20min | <1% | 9,352 | $182K |
| 99460 | <1% | 4,047 | $182K | |
| 87807 | <1% | 12,553 | $179K | |
| 87081 | <1% | 17,476 | $144K | |
| 95816 | <1% | 2,003 | $132K | |
| 83721 | <1% | 22,900 | $131K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 5,354 | $127K |
| 92551 | <1% | 10,232 | $125K | |
| 82607 | <1% | 11,672 | $125K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 442 | $124K |
| 17311 | <1% | 503 | $118K | |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 1,181 | $112K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 700 | $111K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 1,180 | $106K |
| 92004 | Ophthalmological services: medical examination and evaluation, comprehensive, new patient | <1% | 1,957 | $106K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 801 | $105K |
| 90473 | <1% | 5,654 | $105K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 2,295 | $102K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 2,093 | $100K |
| 99174 | <1% | 4,893 | $99K | |
| 97161 | <1% | 2,019 | $98K | |
| 20610 | <1% | 2,375 | $96K | |
| 76770 | <1% | 1,527 | $95K | |
| 95117 | <1% | 7,111 | $94K | |
| 92014 | Ophthalmological services: medical examination and evaluation, comprehensive, established patient | <1% | 2,390 | $94K |
| 81001 | <1% | 30,775 | $93K | |
| 84439 | <1% | 12,105 | $92K | |
| 17110 | <1% | 4,981 | $91K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 288 | $90K |
| 86160 | <1% | 7,897 | $86K | |
| 86200 | <1% | 7,571 | $85K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 1,351 | $84K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 926 | $83K |
| 95165 | Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy, multiple dose vials | <1% | 1,594 | $82K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 10,706 | $80K |
| 95819 | <1% | 958 | $68K | |
| 84481 | <1% | 4,869 | $66K | |
| 86140 | <1% | 13,995 | $65K | |
| 99222 | Initial hospital care, per day, moderate complexity | <1% | 1,517 | $62K |
| 77080 | <1% | 952 | $62K | |
| 99254 | <1% | 687 | $61K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 249 | $57K |
| 95811 | <1% | 357 | $57K | |
| 87428 | <1% | 2,229 | $57K | |
| 86225 | <1% | 4,862 | $54K | |
| 88312 | <1% | 672 | $54K | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 5,840 | $53K |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 6,241 | $52K |
| 86003 | <1% | 866 | $52K | |
| 99243 | <1% | 627 | $52K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,475 | $51K |
| 76536 | <1% | 928 | $50K | |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 435 | $50K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 538 | $50K |
| 86431 | <1% | 8,162 | $49K | |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 276 | $49K |
| 82728 | <1% | 4,470 | $46K | |
| 83655 | <1% | 3,377 | $43K | |
| 72100 | <1% | 1,788 | $43K | |
| 95251 | <1% | 3,021 | $42K | |
| 82550 | <1% | 7,264 | $41K | |
| 80305 | <1% | 3,764 | $41K | |
| 99462 | <1% | 1,651 | $40K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 880 | $39K |
| 99441 | <1% | 1,102 | $39K | |
| 84702 | <1% | 2,632 | $37K | |
| 99223 | Prolong inpt eval add15 m | <1% | 636 | $37K |
| 85652 | <1% | 13,690 | $37K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 473 | $35K |
| 86147 | <1% | 584 | $35K | |
| 81003 | <1% | 26,333 | $34K | |
| 86146 | <1% | 574 | $34K | |
| 93015 | <1% | 603 | $34K | |
| 92567 | <1% | 2,720 | $34K | |
| 94010 | <1% | 1,520 | $33K | |
| 90686 | <1% | 12,998 | $33K | |
| 73630 | <1% | 1,727 | $33K | |
| 73130 | <1% | 1,734 | $32K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 4,946 | $32K |
| 84550 | <1% | 7,087 | $31K | |
| 97150 | Therapeutic procedure(s), group (2 or more individuals) | <1% | 3,137 | $30K |
| 20611 | <1% | 550 | $29K | |
| 82565 | <1% | 6,629 | $29K | |
| 64721 | <1% | 134 | $29K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 474 | $29K |
| 99205 | Prolong outpt/office vis | <1% | 265 | $28K |
| 11103 | <1% | 624 | $28K | |
| 84460 | <1% | 5,863 | $26K | |
| 92558 | <1% | 4,330 | $26K | |
| 94060 | <1% | 740 | $26K | |
| 84450 | <1% | 5,860 | $26K | |
| 92557 | <1% | 1,041 | $26K | |
| 94729 | <1% | 901 | $24K | |
| 82040 | <1% | 5,782 | $24K | |
| 96367 | <1% | 864 | $24K | |
| 82043 | <1% | 5,774 | $23K | |
| 71250 | <1% | 180 | $23K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 1,476 | $23K |
| 93000 | <1% | 1,435 | $23K | |
| 90670 | <1% | 14,069 | $22K | |
| 73560 | <1% | 1,375 | $22K | |
| 92015 | Determination of refractive state | <1% | 2,972 | $22K |
| 83550 | <1% | 3,308 | $22K | |
| 99406 | <1% | 2,764 | $22K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 571 | $20K |
| 97014 | <1% | 2,389 | $20K | |
| 97164 | <1% | 600 | $19K | |
| 82570 | <1% | 5,268 | $19K | |
| 96161 | <1% | 6,795 | $19K | |
| 83540 | <1% | 3,912 | $19K | |
| 99336 | <1% | 556 | $18K | |
| 87070 | <1% | 1,903 | $18K | |
| 31575 | <1% | 386 | $17K | |
| 73610 | <1% | 896 | $17K | |
| 93458 | <1% | 113 | $17K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 432 | $17K |
| 90632 | <1% | 337 | $17K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 277 | $17K |
| 87210 | <1% | 2,932 | $16K | |
| 96160 | <1% | 5,407 | $16K | |
| 99383 | <1% | 175 | $16K | |
| 85610 | <1% | 5,498 | $15K | |
| 51798 | <1% | 1,706 | $15K | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 2,255 | $14K |
| J3490 | Unclassified drugs | <1% | 496 | $14K |
| 99459 | <1% | 1,091 | $13K | |
| 97116 | <1% | 777 | $13K | |
| 11100 | <1% | 545 | $13K | |
| 99442 | <1% | 288 | $12K | |
| 73221 | <1% | 46 | $12K | |
| 96127 | <1% | 3,082 | $12K | |
| 82746 | <1% | 989 | $12K | |
| 86800 | <1% | 993 | $11K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 152 | $11K |
| 73030 | <1% | 546 | $11K | |
| 59410 | <1% | 16 | $11K | |
| 73562 | <1% | 542 | $10K | |
| 87913 | <1% | 41 | $10K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 67 | $10K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 40 | $9K |
| 81025 | <1% | 1,161 | $9K | |
| 86376 | <1% | 791 | $9K | |
| 72040 | <1% | 408 | $9K | |
| 72081 | <1% | 333 | $9K | |
| 72170 | <1% | 497 | $9K | |
| 90723 | <1% | 11,533 | $9K | |
| 90688 | <1% | 712 | $9K | |
| 87186 | <1% | 1,104 | $9K | |
| 85027 | <1% | 1,202 | $8K | |
| 98967 | <1% | 567 | $8K | |
| 95913 | <1% | 40 | $8K | |
| 72202 | <1% | 338 | $8K | |
| 80076 | <1% | 1,253 | $8K | |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | <1% | 126 | $8K |
| 72110 | <1% | 244 | $8K | |
| 17000 | <1% | 380 | $8K | |
| 74178 | <1% | 24 | $7K | |
| 74018 | <1% | 389 | $7K | |
| 99439 | <1% | 222 | $7K | |
| 59430 | <1% | 673 | $7K | |
| 98966 | <1% | 955 | $6K | |
| 69210 | <1% | 382 | $6K | |
| 84403 | <1% | 285 | $6K | |
| 92587 | <1% | 151 | $6K | |
| 99305 | <1% | 407 | $6K | |
| 83735 | <1% | 1,132 | $6K | |
| 97162 | <1% | 123 | $6K | |
| 99382 | <1% | 69 | $6K | |
| 73140 | <1% | 369 | $6K | |
| 90681 | <1% | 4,892 | $6K | |
| 84153 | <1% | 446 | $6K | |
| 59025 | Fetal non-stress test | <1% | 209 | $5K |
| 94726 | <1% | 166 | $5K | |
| 82785 | <1% | 356 | $5K | |
| 95115 | <1% | 474 | $5K | |
| 99308 | Subsequent nursing facility care, per day, straightforward | <1% | 927 | $5K |
| 36415 | Collection of venous blood by venipuncture | <1% | 3,646 | $5K |
| 93299 | <1% | 321 | $5K | |
| 88720 | <1% | 841 | $5K | |
| 52000 | <1% | 68 | $5K | |
| 99239 | Hospital discharge day management, more than 30 minutes | <1% | 143 | $5K |
| 72141 | <1% | 12 | $5K | |
| 96417 | <1% | 109 | $5K | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 45 | $4K |
| 82950 | <1% | 878 | $4K | |
| 87150 | <1% | 163 | $4K | |
| 83615 | <1% | 662 | $4K | |
| L4361 | Walking boot, pneumatic and/or vacuum, with or without joints, with or without interface material, prefabricated, off-the-shelf | <1% | 14 | $4K |
| 90715 | <1% | 359 | $4K | |
| 85018 | <1% | 1,367 | $4K | |
| 90647 | <1% | 11,137 | $4K | |
| 86038 | <1% | 5,525 | $4K | |
| 85014 | <1% | 1,204 | $4K | |
| 73120 | <1% | 235 | $4K | |
| 93298 | <1% | 305 | $3K | |
| 74019 | <1% | 147 | $3K | |
| 86769 | <1% | 112 | $3K | |
| 90651 | <1% | 993 | $3K | |
| 87088 | <1% | 437 | $3K | |
| 92555 | <1% | 295 | $3K | |
| 90633 | <1% | 6,440 | $3K | |
| J2357 | Injection, omalizumab, 5 mg | <1% | 330 | $3K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 36 | $3K |
| G2066 | Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results | <1% | 260 | $3K |
| 90716 | <1% | 3,301 | $3K | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 1,264 | $3K |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 41 | $3K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,701 | $3K |
| 11101 | <1% | 122 | $2K | |
| 95909 | <1% | 24 | $2K | |
| 22853 | <1% | 22 | $2K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 322 | $2K |
| 82465 | <1% | 437 | $2K | |
| 72070 | <1% | 101 | $2K | |
| 90656 | <1% | 891 | $2K | |
| 95024 | <1% | 73 | $2K | |
| 99385 | <1% | 24 | $2K | |
| 72114 | <1% | 54 | $2K | |
| 99349 | <1% | 36 | $2K | |
| 94727 | <1% | 157 | $2K | |
| 0071A | <1% | 60 | $2K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 118 | $2K |
| 90707 | <1% | 3,294 | $2K | |
| 99253 | <1% | 28 | $2K | |
| 83690 | <1% | 324 | $2K | |
| 82150 | <1% | 345 | $2K | |
| 72052 | <1% | 49 | $2K | |
| 84146 | <1% | 110 | $2K | |
| 11104 | <1% | 26 | $2K | |
| 82977 | <1% | 302 | $2K | |
| 73502 | <1% | 82 | $2K | |
| 73564 | <1% | 61 | $2K | |
| 83516 | <1% | 115 | $2K | |
| 90677 | <1% | 1,555 | $1K | |
| L3908 | Wrist hand orthosis, wrist extension control cock-up, non molded, prefabricated, off-the-shelf | <1% | 44 | $1K |
| 97165 | <1% | 31 | $1K | |
| 86308 | <1% | 232 | $1K | |
| 99384 | <1% | 15 | $1K | |
| 99219 | <1% | 24 | $1K | |
| 82670 | <1% | 54 | $1K | |
| 92136 | <1% | 110 | $1K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 474 | $1K |
| 86008 | <1% | 30 | $1K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 36 | $1K |
| 86318 | <1% | 62 | $1K | |
| 90734 | <1% | 788 | $1K | |
| 96415 | <1% | 40 | $1K | |
| 90671 | <1% | 929 | $1K | |
| 93018 | <1% | 68 | $987.30 | |
| 54150 | <1% | 12 | $957.96 | |
| 99242 | <1% | 13 | $938.95 | |
| 99231 | Subsequent hospital care, per day, straightforward or low complexity | <1% | 76 | $926.28 |
| 99152 | <1% | 153 | $914.22 | |
| 17003 | <1% | 42 | $872.42 | |
| 13132 | <1% | 13 | $869.14 | |
| 84520 | <1% | 217 | $838.50 | |
| 93923 | <1% | 45 | $834.82 | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 16 | $808.62 |
| 84100 | <1% | 227 | $795.20 | |
| 93016 | <1% | 39 | $764.53 | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 48 | $755.96 |
| 0072A | <1% | 16 | $695.50 | |
| 92588 | <1% | 12 | $694.15 | |
| 99307 | <1% | 57 | $685.54 | |
| 92552 | <1% | 57 | $676.68 | |
| 85045 | <1% | 251 | $640.69 | |
| 93244 | <1% | 42 | $608.20 | |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | <1% | 733 | $592.49 |
| 99335 | <1% | 12 | $580.60 | |
| 74420 | <1% | 55 | $550.11 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 101 | $546.18 |
| 90674 | <1% | 29 | $544.08 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 200 | $532.25 |
| 90380 | <1% | 26 | $485.13 | |
| 90682 | <1% | 24 | $468.74 | |
| 82947 | <1% | 143 | $438.62 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 38 | $427.26 |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 76 | $418.42 |
| 92133 | <1% | 17 | $390.64 | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 44 | $378.56 |
| 99217 | <1% | 14 | $373.83 | |
| G2012 | Brief communication technology-based service, e.g. virtual check-in, by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related e/m service provided within the previous 7 days nor leading to an e/m service or procedure within the next 24 hours or soonest available appointment; 5-10 minutes of medical discussion | <1% | 57 | $367.46 |
| 86803 | <1% | 548 | $355.09 | |
| 93242 | <1% | 42 | $352.27 | |
| 99304 | <1% | 26 | $351.25 | |
| 84703 | <1% | 24 | $342.81 | |
| 90685 | <1% | 627 | $339.25 | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 27 | $317.82 |
| 92504 | <1% | 34 | $308.65 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 653 | $305.33 |
| 90672 | <1% | 518 | $292.51 | |
| 73070 | <1% | 14 | $279.97 | |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 17 | $276.46 |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 30 | $271.51 |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 99 | $269.14 |
| 86850 | <1% | 909 | $251.93 | |
| 83525 | <1% | 26 | $242.54 | |
| 87340 | <1% | 265 | $228.91 | |
| 84480 | <1% | 12 | $216.63 | |
| 84681 | <1% | 12 | $209.78 | |
| 82533 | <1% | 14 | $192.83 | |
| J2780 | Injection, ranitidine hydrochloride, 25 mg | <1% | 30 | $189.29 |
| 80055 | <1% | 243 | $185.13 | |
| 73565 | <1% | 12 | $184.91 | |
| 82784 | <1% | 27 | $176.96 | |
| 90696 | <1% | 420 | $162.47 | |
| 90710 | <1% | 173 | $157.64 | |
| 95012 | <1% | 22 | $152.14 | |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | <1% | 363 | $135.09 |
| 84436 | <1% | 12 | $109.51 | |
| 84156 | <1% | 44 | $106.28 | |
| 76937 | <1% | 18 | $100.00 | |
| 99497 | <1% | 90 | $93.02 | |
| 84478 | <1% | 15 | $88.04 | |
| 86787 | <1% | 183 | $87.24 | |
| 99318 | <1% | 24 | $86.75 | |
| 90700 | <1% | 502 | $80.36 | |
| 86702 | <1% | 408 | $79.66 | |
| 88150 | <1% | 5,620 | $69.01 | |
| 80164 | <1% | 13 | $66.36 | |
| 85730 | <1% | 12 | $48.48 | |
| 86708 | <1% | 91 | $42.22 | |
| 86704 | <1% | 93 | $41.01 | |
| G0008 | Administration of influenza virus vaccine | <1% | 167 | $39.96 |
| 86762 | <1% | 119 | $38.57 | |
| 86706 | <1% | 93 | $36.62 | |
| 83020 | <1% | 75 | $25.74 | |
| 86900 | <1% | 132 | $5.02 | |
| 86901 | <1% | 132 | $5.02 | |
| 86592 | <1% | 104 | $4.27 | |
| 86593 | <1% | 91 | $2.99 | |
| J7611 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg | <1% | 37 | $2.12 |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | 0% | 808 | $0.00 |
| 87535 | 0% | 49 | $0.00 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 0% | 98 | $0.00 |
| 85007 | 0% | 154 | $0.00 | |
| 81329 | 0% | 12 | $0.00 | |
| 81422 | 0% | 14 | $0.00 | |
| 87538 | 0% | 49 | $0.00 | |
| 888888 | 0% | 222 | $0.00 | |
| 81290 | 0% | 12 | $0.00 | |
| 81260 | 0% | 12 | $0.00 | |
| 86480 | 0% | 12 | $0.00 | |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 0% | 46 | $0.00 |
| 84466 | 0% | 16 | $0.00 | |
| 81420 | Fetal chromosomal aneuploidy genomic sequence analysis panel | 0% | 14 | $0.00 |
| 86705 | 0% | 27 | $0.00 | |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | 0% | 12 | $0.00 |
| 81257 | 0% | 12 | $0.00 | |
| 87481 | 0% | 13 | $0.00 | |
| 82652 | 0% | 12 | $0.00 | |
| 81243 | 0% | 12 | $0.00 | |
| 99024 | 0% | 1,032 | $0.00 | |
| 81361 | 0% | 12 | $0.00 | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | 0% | 93 | $0.00 |
| 81374 | 0% | 13 | $0.00 | |
| 81330 | 0% | 12 | $0.00 | |
| 90620 | 0% | 40 | $0.00 | |
| 81209 | 0% | 12 | $0.00 | |
| 81242 | 0% | 12 | $0.00 | |
| 90660 | 0% | 55 | $0.00 | |
| 87529 | 0% | 33 | $0.00 | |
| 87521 | Neg quan hep c or qual rna | 0% | 13 | $0.00 |
| 81255 | 0% | 12 | $0.00 | |
| 81251 | 0% | 12 | $0.00 | |
| 81200 | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialD'ERAMO, MICHAEL (CEO)
Parent organizationGGC HEALTH, PLLC